Design of a phase II dose range finding, efficacy and safety study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in relapsing multiple sclerosis patients

被引：0
|
作者：
Montalban, X. [1 ]
Bojanowski, J. [2 ]
Martin, E. [2 ]
Willmer, J. [2 ]
机构：
[1] Vall dHebron Univ Hosp & Res Inst, Barcelona, Spain
[2] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P675
引用
收藏
页码：324 / 324
页数：1
相关论文
共 50 条
  • [31] Evobrutinib Efficacy is Maintained Over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin S.
    Staikov, Ivan
    Piasecka-Stryczynska, Karolina
    Martin, Emily C.
    Mandel, Matthew
    Dangond, Fernando
    Wolinsky, Jerry S.
    NEUROLOGY, 2021, 96 (15)
  • [32] Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study
    Papasouliotis, Orestis
    Mitchell, David
    Girard, Pascal
    Dangond, Fernando
    Dyroff, Martin
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (12): : 2888 - 2898
  • [33] Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin S.
    Staikov, Ivan
    Piasecka-Stryczynska, Karolina
    Martin, Emily C.
    Mandel, Matthew
    Zima, Yulia
    Shaw, Jamie
    Dangond, Fernando
    Grenningloh, Roland
    Li, Ying
    Tomic, Davorka
    Wolinsky, Jerry S.
    NEUROLOGY, 2021, 96 (15)
  • [34] SAFETY AND EFFICACY OF THE BRUTON TYROSINE KINASE INHIBITOR IBRUTINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA: INTERIM RESULTS OF A PHASE 2 STUDY
    Jones, J. A.
    Andritsos, L.
    Ravandi, F.
    Kreitman, R. J.
    Schiffer, C.
    Call, T.
    Lozanski, G.
    Sexton, J.
    Harris, P.
    Grever, M. R.
    HAEMATOLOGICA, 2015, 100 : 313 - 313
  • [35] Update on long-term safety and efficacy of evobrutinib, a Bruton's tyrosine kinase inhibitor, over 5 years from an ongoing Phase 2 open-label extension
    Montalban, Xavier
    Wolinsky, Jerry
    Arnold, Douglas L.
    Weber, Martin
    Stryczynska, Karolina
    Starossom, Sarah C.
    Meier, Daniela Piani
    Seitzinger, Andrea
    Guehring, Hans
    Tomic, Davorka
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 610 - 611
  • [36] Maintenance of efficacy, safety and tolerability of ponesimod in patients with relapsing remitting multiple sclerosis: phase II extension study
    Pozzilli, C.
    Fernandez, O.
    Olsson, T.
    Freedman, M. S.
    Melanson, M.
    Boster, A.
    Radue, E-W
    Hennessy, B.
    Rames, A.
    D'Ambrosio, D.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 456 - 457
  • [37] Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
    Cooper, Nichola
    Jansen, A. J. Gerard
    Bird, Robert
    Mayer, Jiri
    Sholzberg, Michelle
    Tarantino, Michael D.
    Garg, Mamta
    Ypma, Paula F.
    Mcdonald, Vickie
    Percy, Charles
    Kostal, Milan
    Goncalves, Isaac
    Bogdanov, Lachezar H.
    Gernsheimer, Terry B.
    Diab, Remco
    Yao, Mengjie
    Daak, Ahmed
    Kuter, David J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (03) : 439 - 449
  • [38] Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study
    Jones, Jeffrey
    Andritsos, Leslie
    Kreitman, Robert J.
    Ravandi, Farhad
    Schiffer, Charles
    Call, Timothy G.
    Lozanski, Gerard
    Harris, Pamela
    Sexton, Jennifer
    Ruppert, Amy S.
    Grever, Michael R.
    BLOOD, 2016, 128 (22)
  • [39] Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia
    Kuter, David J.
    Tzvetkov, Nikolay
    Efraim, Merlin
    Kaplan, Zane
    Mayer, Jiri
    Choi, Philip
    Jansen, A. J. Gerard
    McDonald, Vickie
    Baker, Ross
    Bird, Robert J.
    Garg, Mamta
    Gumulec, Jaromir
    Kostal, Milan
    Gernsheimer, Terry
    Ghanima, Waleed
    Bandman, Olga
    Arora, Puneet
    Burns, Regan
    Yao, Mengjie
    Daak, Ahmed
    Sourdille, Timothee
    Iqbal, Fareha
    Thomas, Dolca
    Neale, Ann
    Cooper, Nichola
    BLOOD, 2021, 138
  • [40] A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenstrom Macroglobulinemia (WM)
    Kingsley, Edwin C.
    Fabre, Shannon
    Takai, Motohisa
    Cohen, Aileen Cleary
    Schneider, Jingjing
    Li, Jessica
    D'Olimpio, James
    BLOOD, 2023, 142
12345